Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Brian Flynn, Michael Loffredo Outline Market Trends in Packaging Strategies

    Brian Flynn and Michael Loffredo discuss how energy prices, digital printing, and sustainability regulations could shape packaging M&A activity.

    Read more

  • Rapport Therapeutics, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Rapport Therapeutics, Inc., a clinical-stage leader in developing therapies targeting receptor-associated proteins focused on treating neurology and neuropsychiatry disorders of high unmet clinical need.

    Read more

  • AI Adoption in Enterprise: Real Progress, Uneven Execution

    Enterprise AI is making real progress, but adoption is anything but even. Here’s where momentum is strongest and what’s still holding back the broader rollout.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures